Other Events ·
NovaBridge Biosciences filed a Form 6-K to furnish an investor presentation dated August 20, 2026
IMABNovaBridge Biosciences
NovaBridge Biosciences filed a Form 6-K to furnish an investor presentation dated August 20, 2026. The company reported approximately $216 million in cash and investments as of June 30, 2026, maintaining a debt-free balance sheet. Key clinical milestones include plans to initiate Phase 3 trials for givastomig as early as year-end 2026 and Phase 2b studies for VIS-101 in the second half of 2026. The presentation highlighted ongoing financing discussions and partnership negotiations for its oncology and ophthalmology franchises, alongside a signed term sheet for asset VIS-102. NovaBridge Biosciences operates as a clinical-stage biotechnology company focused on developing differentiated therapies for oncology and rare diseases.